On Sunday, December 21, the Facilities for Medicare & Medicaid Companies (CMS) introduced in two separate press releases that it’s proposing new drug fee fashions to handle rising drug prices in Medicare Half D and Half B. In response to the information launch, the Guarding U.S. Medicare In opposition to Rising Drug Prices (GUARD) Mannequin and the International Benchmark for Environment friendly Drug Pricing (GLOBE) Mannequin are anticipated to decrease spending for Medicare beneficiaries with out hurting their high quality of care whereas additionally bettering the sustainability of the Medicare program and the Medicare Belief Fund and defending innovation.
Individuals pay, on common, thrice what different developed nations pay for a similar drugs, CMS said. Medicare Half D drug spending in 2024 made up about 30 % of drug spending within the U.S. In response to the Well being and Human Companies Secretary (HHS) Workplace of the Assistant Secretary for Planning and Analysis, drug spending in Medicare Half B was practically 4 occasions greater than drug spending throughout all payers (Medicare, Medicaid, industrial) between 2008 and 2021.
CMS outlined two proposed fashions—GUARD and GLOBE—that might check new approaches to calculating Medicare drug inflation rebates by incorporating worldwide pricing benchmarks. The GUARD Mannequin would apply to Medicare Half D outpatient prescribed drugs and would regulate the inflation rebate formulation by factoring in costs paid for comparable medication in economically comparable nations, whereas incorporating present producer rebates and reductions. The GLOBE Mannequin would take a parallel strategy for sure individually payable Medicare Half B medication administered in scientific settings, modifying the inflation rebate calculation utilizing worldwide drug pricing information. Collectively, the fashions purpose to judge whether or not aligning rebate calculations extra carefully with world costs can cut back Medicare program spending whereas sustaining or bettering the standard of look after beneficiaries.
“On Could 12, President Trump ordered an all-of-government response to the unfair hole between U.S. drug costs and what different nations pay,” HHS Robert F. Kennedy, Jr., mentioned in an announcement. “CMS is answering that decision with two new fashions underneath Components B and D that tie drug costs and rebates to prices in comparable nations.”
The GUARD Mannequin would start Jan. 1, 2027, and function for 5 years with rebate invoicing and fee persevering with till 2033. The mannequin would cowl 25 % of Half D enrollees and apply solely to beneficiaries residing in randomly chosen geographic areas of the nation.
GLOBE inclusion standards would exclude biosimilars and their reference biologics as soon as a biosimilar is accredited in the USA. The GLOBE Mannequin would additionally function for 5 years, from Oct. 1, 2026, to Sept. 30, 2031, with rebate invoicing and reconciliation persevering with till Sept. 30, 2033. Much like the GUARD Mannequin, the GLOBE mannequin would apply to Medicare beneficiaries residing in an outlined geographic space, representing roughly 25 % of the Medicare beneficiary inhabitants in the USA.
